Bausch + Lomb Receives FDA Approval of enVista IOL
Bausch + Lomb has announced it has received FDA approval for the enVista hydrophobic acrylic intraocular lens, according to a news release.
Bausch + Lomb's said it is the only FDA-approved IOL in the United States with labeling that states "No glistenings of any grade were reported for any subject at any visit in the clinical study." Glistenings are fluid-filled microvacuoles that can form within an IOL and may impact visual function, according to the release.
"The enVista IOL is yet another example of how Bausch + Lomb is advancing eye health innovation to meet the needs of our customers and the patients they serve," said Cal Roberts, MD, executive vice president and chief medical officer for Bausch + Lomb, in the release. "We've listened to our customers tell us how frustrating glistenings can be when conducting post-surgical examinations of their patients. We are proud to offer them an attractive, viable and technologically-advanced option to address this concern."
Bausch + Lomb's world headquarters is in Rochester, N.Y.
Related Articles on FDA Approval:
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
- House Votes to Repeal the PPACA — for 37th Time
- 6 Statistics on Concierge and Direct Pay Physician Practices
- Best Practices: Documentation and Reporting for Post-Operative Pain Management Procedures in Anesthesia
- 5 Things to Know About Medical Office Visits in 2012
- Medical Facilities Corporation Reports Higher Revenue After Arkansas Surgical Hospital Acquisition